

MAY 04 2004



PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/640,989
		Filing Date	August 14, 2003
		First Named Inventor	YANG
		Art Unit	1651
		Examiner Name	
Total Number of Pages in This Submission		Attorney Docket Number	5853-261

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	PTO/SB/08B; 25 Reference; and 1 Postcard.
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Neil R. Jetter AKERMAN SENTERFITT
Signature	
Date	April 30, 2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450; Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Neil R. Jetter
Signature	
Date	April 30, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: YANG

Application No.: 10/640,989

Examiner:

Filed: August 14, 2003

Group Art Unit: 1651

For: BONE MARROW CELL DIFFERENTIATION

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on April 30, 2004.

Neil R. Letter

Mail Stop Amendment
Commissioner for Patents
Post Office Box 1450
Alexandria, VA 22313-1450

Date: April 30, 2004

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the Duty to Disclose under 37 C.F.R. §1.56, Applicant hereby discloses information that may be relevant to the Examiner's consideration of the above-identified application and the patentability of its claims.


In accordance with Rules 56, 97, and 98 of the Rules of Practice in Patent Cases (37 C.F.R. §§ 1.56, 1.97, and 1.98), Form PTO/SB/08B with references cited therein are submitted for consideration by the Examiner. While the references provided in this Information Disclosure Statement may be material to patentability pursuant to 37 C.F.R. § 1.56, it is not intended to constitute an admission that any reference referred to herein is prior art for this invention unless specially designated as such. Also, in accordance with 37 C.F.R. § 1.97(g), the

In re Application of: YANG
Application No.: 10/640,989
Filed: August 14, 2003
Group Art Unit:
For: BONE MARROW CELL DIFFERENTIATION

filings of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(a) exists.

This Information Disclosure Statement is being filed before the issuance of a first office action on the merits of the application (37 C.F.R. 1.97(b)(3)); therefore, no fee is believed to be due. However, if any fee is due, the Commissioner is authorized to charge any such fee and any additional fees due or credit any overpayment to Deposit Account No. 50-0951.

Respectfully submitted,



Neil R. Jetter, Reg. No. 46,803
AKERMAN SENTERFITT
222 Lakeview Avenue, Suite 400
Post Office Box 3188
West Palm Beach, FL 33402-3188
Telephone: (561) 653-5000
Facsimile: (561) 659-6313

Docket No. 5853-261



MAY 04 2004

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/640,989
				Filing Date	August 14, 2003
				First Named Inventor	YANG
				Art Unit	1651
				Examiner Name	
Sheet	1	of	3	Attorney Docket Number	5853-261

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
		BUSCHARD et al., "Neonatal treatment with beta-cell stimulatory agents reduces the incidence of diabetes in BB rats," Int. J. Exp. Diabetes Res. 1:1-8, 2000.				
		HOHMEIER et al., "ISOLATION OF INS-1-DERIVED CELL LINES WITH ROBUST ATP-SENSITIVE K+ CHANNEL-DEPENDENT AND-INDEPENDENT GLUCOSE-STIMULATED INSULIN SECRETION," Diabetes 49: 424-430, 2000.				
		SHAPIRO et al., "Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen," N. Engl. J. Med. 343:230-238, 2000.				
		YANG et al., "In Vitro trans-differentiation of adult hepatic stem cells into pancreatic endocrine hormone-producing cells," PNAS 99:8078-8083, 2002.				
		DEUTSCH et al., "A bipotential precursor population for pancreas and liver within the embryonic endoderm," Development 128:871-881, 2001.				
		REYES et al., "Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells," Blood 98:2615-2625, 2001.				
		BONNER-WEIR, "In vitro cultivation of human islets from expanded ductal tissue," PNAS 97:7999-8004, 2000.				
		RAMIYA et al., "Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells," Nat.Med. 6:278-282, 2000.				
		IANUS et al., "In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion," J.Clin.Invest 111:843-850, 2003.				
		RAJAGOPAL et al., "Insulin Staining of ES Cell Progeny from Insulin Uptake," Science 299:363, 2003.				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/640,989
				Filing Date	August 14, 2003
				First Named Inventor	YANG
				Art Unit	1651
				Examiner Name	
Sheet	2	of	3	Attorney Docket Number	5853-261

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
		XU et al., "Exendin-4 Stimulates Both Beta-Cell Replication and Neogenesis, Resulting in Increased Beta-Cell Mass and Improved Glucose Tolerance in Diabetic Rats," Diabetes 48:2270-2276, 1999.		
		AKIYAMA et al., "Activation of Reg gene, a gene for insulin-producing beta-cell regeneration: Poly(ADP-ribose) polymerase binds Reg promoter and regulates the transcription by autopoly (ADP-ribosylation). PNAS 98:48-53, 2001.		
		KOJIMA et al., "NeuroD-beta cellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice," Nature Medicine 9:596-603, 2003.		
		CORNELIUS et al., "In vitro-generation of islets in long-term cultures of pluripotent stem cells from adult mouse pancreas," Horm Metab. Res. 29: 271-277, 1997.		
		LUMELSKY et al., "Differentiation of Embryonic Stem Cells to Insulin-Secreting Structures Similar to Pancreatic Islets," Science 292:1389-1394, 2001.		
		ASSADY et al., "Insulin Production by Human Embryonic Stem Cells," Diabetes 50:1691-1697, 2001.		
		PETERSEN et al., "Bone Marrow as a Potential Source of Hepatic Oval Cells," Science 284:1168-1170, 1999.		
		OTONKOSKI et al., "Nicotinamide is a potent inducer of endocrine differentiation in cultured human fetal pancreatic cells," J. Clin. Invest. 92:1459-1466, 1993.		
		SORIA et al., "From stem cells to beta cells: new strategies in cell therapy of diabetes mellitus," Diabetologia 44:407-415, 2001.		
		ZULEWSKI et al., "Multipotential Nestin-Positive Stem Cells Isolated From Adult Pancreatic Islets Differentiate Ex Vivo Into Pancreatic Endocrine, Exocrine, and Hepatic Phenotypes," Diabetes 50:521-533, 2001.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/640,989
Sheet	3	of	3	Filing Date	August 14, 2003
				First Named Inventor	YANG
				Art Unit	1651
				Examiner Name	
				Attorney Docket Number	5853-261

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		SJOHOLM et al. "Role of polyamines in mitogenic and secretory responses of pancreatic beta-cells to growth factors," Am J. Physiol. 259:C828-C833, 1990.			T ²
		VOGEL, "Same Results, Different Interpretations," Science 299:324, 2003.			
		HESS et al., "Bone-marrow-derived stem cells initiate pancreatic regeneration," Nature Biotechnology 21:763-770, 2003.			
		DENG et al., "Neural trans-differentiation potential of hepatic oval cells in the neonatal mouse brain," Experimental Neurology 182:373-382, 2003.			
		HELLERSTROM et al., "Functional Maturation and Proliferation of Fear Pancreatic B-Cells," Diabetes 40:89-93, 1991.			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.